An experimental drug called EscharEx, based on enzymes extracted from pineapple, is now being tested in an international phase 3 clinical trial for venous leg ulcers. The study has approval from Israel’s Health Ministry, the US FDA, and the European Medicines Agency, and several medical centers in Israel are taking part.
In an interview with ynet, Prof. Yossi Chayek, head of plastic and aesthetic surgery, the national burns intensive care center, and the skin bank at Sheba Medical Center, explained how the treatment works. He said the pineapple-derived enzyme can precisely remove damaged tissue while leaving healthy tissue intact. He added that this approach has already changed burn care by reducing the need for surgery, and that the team is now exploring broader uses for chronic wounds.
Chayek said many wounds cannot be treated surgically, especially at the first stage, because most patients are medically complex. He said earlier studies showed better results than standard treatments and placebo. According to him, if a wound normally takes two months to clean, the drug could make it clean within 10 to 14 days, helping it close and making surgery easier if one is still needed.
The trial is recruiting patients with venous ulcers in the legs. In Israel, it is being conducted at Sheba, Kaplan, Shamir, and Rabin medical centers. Participants receive medical follow-up, protocol-based treatment, and transportation assistance to the study sites. Those interested can contact Ruti at 054-796-6000 or register at www.thevaluetrial.co.il.
